LS
TEVA icon

Leelyn Smith’s Teva Pharmaceuticals TEVA Stock Holding History

Leelyn Smith’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-200
Closed -$2K – 387
2021
Q1 		$2K Hold
200
– – ﹤0.01% 359
2020
Q4 		$2K Buy
+200
New +$1.92K ﹤0.01% 335

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Leelyn Smith's TEVA Position: Q2 2021 in Review

Leelyn Smith sold out of Teva Pharmaceuticals (TEVA) in Q2 2021, closing a stake of 200 shares — an estimated $2K sold.

Leelyn Smith first reported a position in TEVA in Q4 2020 and held it in 2 quarters. The position peaked at $2K in Q1 2021. 440 funds tracked by Wall St. Rank hold TEVA as of Q2 2021.

  • Leelyn Smith reported no remaining Teva Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Leelyn Smith sold 200 Teva Pharmaceuticals shares in Q2 2021, an estimated $2K.
  • Leelyn Smith first reported a position in Teva Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Leelyn Smith's Teva Pharmaceuticals position peaked at $2K in Q1 2021.
  • 440 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2021.

Based on Leelyn Smith's 13F filing for Q2 2021, filed 31 Aug 2021.